ASCO 2022

Conference Coverage

Geriatric Screening and CARG Toxicity Assessment Tools Predict Adverse Outcomes

Geriatric Screening and CARG chemotherapy toxicity assessment tools were found in a study to predict adverse outcomes in older patients with cancer.

Acupuncture Improves Symptoms of Radiation-Induced Xerostomia in Head and Neck Cancer

Acupuncture was associated with improvements in symptoms and quality of life.

Rusfertide for Patients With Phlebotomy-Dependent Polycythemia Vera

Rusfertide demonstrated activity in reducing hematocrit levels in patients with polycythemia vera in two phase 2 clinical trials.

Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer

There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.

Rivoceranib Appears Active in Recurrent, Metastatic Adenoid Cystic Carcinoma

Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.

Predictive Value of ECOG Performance Status in ‘Real World’ Patient Populations

A study showed the predictive value of Eastern Cooperative Oncology Group performance status in a real-world cohort of patients.

Care Sequence Model With Follow-Up Improves Advance Directive Completion Rates in Breast Cancer

Researchers compared preoperative patient care methods to find a method that could improve advance directive completion rates in patients undergoing surgery for newly diagnosed breast cancer.

Nurse Navigators Increase Geriatric and Toxicity Screening, Referrals to Supportive Services

A pilot study delegated screening assessments to nurse navigators to determine if such a program would increase referrals to supportive services for older older patients.

Rituximab Plus Axi-Cel Induced High Response Rates in Large B-Cell Lymphoma

Researchers sought to determine whether adding rituximab to axicabtagene ciloleucel would have efficacy in patients with refractory large B-cell lymphoma.

ADT, Disease Transition Are Risk Factors for Depression, Anxiety in Prostate Cancer

A survey of men with prostate cancer sought to identify when these patients were most vulnerable to symptoms of depression and/or anxiety.

Zanubrutinib May Improve Response Rate Compared With Ibrutinib in Waldenström Macroglobulinemia

Researchers sough to determine whether zanubrutinib would improve responses compared with ibrutinib in patients with Waldenström macroglobulinemia.

CD7 CAR-T Therapy Induced Remission in R/R T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Preliminary results of a clinical trial investigating the efficacy of CAR-T therapy in pediatric patients with CD7+ ALL/lymphoma were presented at ASCO 2022.

Trastuzumab Deruxtecan Deemed “Practice-Changing” for HER2-Low Metastatic Breast Cancer

Trastuzumab deruxtecan improved progression-free and overall survival, compared with physician’s choice of therapy.

The Effect of Gender Bias in Surveys of Patients With Myeloproliferative Neoplasm

Gender balance in cancer surveys was found to have relatively little effect on survey outcomes, according to results of a study presented at the 2022 ASCO Annual Meeting. Surveying patients with myeloproliferative neoplasms (MPN) has given valuable insight into polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF) subtypes. However, independent surveys have included a…

Data Reveal Disparities in Telemedicine Use Among Patients With Cancer

Researchers found that socioeconomic status, insurance, race, and rurality were all associated with telemedicine use.

High-Dose Ifosfamide Bests Topotecan-Cyclophosphamide in Relapsed/Refractory Ewing Sarcoma

Ifosfamide improved event-free and overall survival.

Lack of Access, Not Lack of Interest, Prevents Black Patients From Enrolling in Clinical Trials

More than 80% of Black survey respondents said they were somewhat or very likely to consider enrolling in a clinical trial.

Increasing Public Welfare Spending Can Improve Survival for Black Cancer Patients

A 10% increase in public welfare spending was associated with an 8.6% improvement in 5-year overall survival for Black patients with cancer.